Merck profit beats as research trimmed

(Reuters) - Merck & Co on Thursday reported better-than-expected fourth-quarter earnings, helped by a decrease in research spending, and predicted relatively flat 2012 results as the No. 2 U.S. drugmaker girds for cheaper generic forms of its biggest product, asthma drug Singulair. Merck posted a fourth-quarter net profit of $1.51 billion, or 49 cents per share, compared with a loss of $531 ...

Merck's 4Q Tops Expectations, R&D Costs Down

Merck & Co (MRK.N) on Thursday reported better-than-expected fourth-quarterearnings, helped by a decrease in research spending, and predicted relatively flat 2012 results as the No. 2 U.S. drugmaker girds for cheaper generic forms of its biggest product, asthma drug Singulair.

Merck profit beats expectations on lower R&D, taxes - Reuters

Merck profit beats expectations on lower R&D, taxes Reuters They include two products that have been delayed for years by regulators: Bridion, to reverse the effects of anesthesia, and Tredaptive, a form of niacin meant to raise "good" HDL cholesterol without causing facial flushing. The company said it expects ... and more »

Vitamins From A to Z - AARP News

AARP News

Vitamins From A to Z AARP News Women: 14 mg Why you need it: Niacin is necessary for the proper functioning of the digestive system, skin and nerves; helps convert food to energy. Good to know: Can cause skin flushing; may be prescribed to treat high cholesterol but should be used ...

Message: This news feed will stop on Jan 23 2012. Thank you for your custom.

Sponsored Link